Cleo Diagnostics Ltd (ASX:COV) Files Patent Applications for Ovarian Cancer Screening Test Development

Sonal Goyal

30 September 2026 02:23 PM AEST

Cleo Diagnostics Ltd (ASX:COV) Files Patent Applications for Ovarian Cancer Screening Test Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Cleo Diagnostics Ltd (ASX:COV) filed two provisional Patent applications related to its ovarian cancer screening test development program.
The patent filings cover candidate biomarker combinations and their application in early detection of ovarian cancer.
The company plans to establish intellectual property protection ahead of initial proof-of-concept screening data expected in Q4 CY2026.
The new filings expand Cleo’s intellectual property portfolio alongside its existing ovarian cancer diagnostic development programs.

Cleo Diagnostics Ltd (ASX:COV) is an Australian medical technology company developing diagnostic solutions for ovarian cancer detection. The company’s shares were trading at AUD 0.30, up nearly 6% on 30 September 2026 at 1:16 pm. Cleo Diagnostics has announced the filing of two provisional patent applications to protect intellectual property generated through the development of its ovarian cancer screening test program.

Patent Applications Support Screening Test Development

Cleo Diagnostics has filed two new provisional patent applications focused on candidate biomarker combinations and their application for early detection of ovarian cancer.

The filings follow the company’s recent commencement of its screening development program and are intended to establish an initial intellectual property priority position around technologies being developed within the program.

Cleo Diagnostics plans to file an international application under the Patent Cooperation Treaty (PCT) within the 12-month priority period. The company aims to seek protection across selected commercial markets as development activities continue.

The patent applications were submitted before the release of the company’s initial proof-of-concept screening data, which is expected in Q4 CY2026.

Expanding Ovarian Cancer Diagnostic Platform

The screening test program builds on Cleo Diagnostics’ existing biomarker platform and clinical expertise developed through its Pre-Surgical Ovarian Cancer Test program.

The company is progressing multiple applications of its biomarker technology across different stages of ovarian cancer detection, including pre-surgical assessment, recurrence monitoring and potential future screening applications.

Cleo’s technology platform is based on the CXCL10 biomarker, which has been developed through more than 15 years of scientific research and development.

The company is applying its biomarker expertise to develop diagnostic approaches aimed at supporting earlier identification of ovarian cancer.

Development Pathway and Future Activities

Cleo Diagnostics is continuing development of its screening test while protecting intellectual property generated during the program.

The company expects proof-of-concept screening data in Q4 CY2026, which will provide additional information on the progress of the screening test development program.

The company is also advancing its Pre-Surgical Ovarian Cancer Test program, which is progressing towards planned regulatory activities.

Cleo Diagnostics’ broader strategy involves applying its biomarker technology across the ovarian cancer detection pathway, with development programs focused on different clinical applications.

Ovarian Cancer Diagnostic Opportunity

Ovarian cancer remains a significant healthcare challenge due to difficulties associated with early detection. Cleo Diagnostics is developing blood-based diagnostic technologies aimed at improving detection capabilities.

The company’s CXCL10 biomarker technology forms the basis of its diagnostic approach. Cleo states that CXCL10 is produced early in ovarian cancer and may assist in distinguishing malignant conditions from benign disease.

The company is pursuing a staged development approach, beginning with its pre-surgical triage test program and extending towards recurrence monitoring and broader screening applications.

Risks and Uncertainty

Medical technology development involves risks related to clinical validation, regulatory approvals, intellectual property protection, funding requirements and commercial adoption. Patent filings provide intellectual property protection but do not confirm successful product development, regulatory approval or commercialisation.

Diagnostic technologies require further clinical evaluation and validation before they can be adopted for broader healthcare applications.

Bottom Line

Cleo Diagnostics’ latest patent filings represent an intellectual property milestone within its ovarian cancer screening test development program. The company is continuing to advance its biomarker-based diagnostic platform while preparing for proof-of-concept screening data expected in Q4 CY2026. Further clinical, regulatory and development activities will determine the future progress of the technology.

FAQs

Q: What did Cleo Diagnostics file patents for?

A: Cleo Diagnostics filed two provisional patent applications covering candidate biomarker combinations and their application in early detection of ovarian cancer.

Q: What is the purpose of the patent filings?

A: The filings are intended to establish an initial intellectual property position around technologies developed through Cleo’s ovarian cancer screening program.

Q: When is Cleo Diagnostics expecting initial screening data?

A: The company expects initial proof-of-concept screening data in Q4 CY2026.

Q: What biomarker technology does Cleo Diagnostics use?

A: Cleo Diagnostics’ technology platform is based on the CXCL10 biomarker.

Q: What other diagnostic program is Cleo Diagnostics advancing?

A: The company is also progressing its Pre-Surgical Ovarian Cancer Test program, which is being developed alongside its screening test initiatives.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.